Tags

Type your tag names separated by a space and hit enter

IgA antigliadin antibodies as a screening method for nonovert celiac disease in children with insulin-dependent diabetes mellitus.
J Pediatr Gastroenterol Nutr 1996; 23(1):29-33JP

Abstract

One hundred forty-one children with insulin-dependent diabetes mellitus were screened for serum immunoglobulin A (IgA) antigliadin antibodies by means of an enzyme-linked immunosorbent assay (ELISA) method. None of them had gastrointestinal symptoms, and no major nutritional disturbances were detected except for a girl with moderate growth delay. Twelve patients with positive IgA antigliadin antibodies on two or more consecutive measurements underwent a small intestinal biopsy; four of them had a subtotal villous atrophy, and celiac disease was diagnosed; in another patient, a partial villous atrophy was observed. Children suffering from both diabetes and celiac disease showed an onset of diabetes at a younger age than did nonceliac patients. Prevalence of celiac disease in the screened population is 2.85%, which is higher than in the general population of the Comunidad Valenciana (one in 2,500 live births).

Authors+Show Affiliations

Endocrinology and Gastroenterology Units, La Fe Children's Hospital, Valencia, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

8811520

Citation

Calero, P, et al. "IgA Antigliadin Antibodies as a Screening Method for Nonovert Celiac Disease in Children With Insulin-dependent Diabetes Mellitus." Journal of Pediatric Gastroenterology and Nutrition, vol. 23, no. 1, 1996, pp. 29-33.
Calero P, Ribes-Koninckx C, Albiach V, et al. IgA antigliadin antibodies as a screening method for nonovert celiac disease in children with insulin-dependent diabetes mellitus. J Pediatr Gastroenterol Nutr. 1996;23(1):29-33.
Calero, P., Ribes-Koninckx, C., Albiach, V., Carles, C., & Ferrer, J. (1996). IgA antigliadin antibodies as a screening method for nonovert celiac disease in children with insulin-dependent diabetes mellitus. Journal of Pediatric Gastroenterology and Nutrition, 23(1), pp. 29-33.
Calero P, et al. IgA Antigliadin Antibodies as a Screening Method for Nonovert Celiac Disease in Children With Insulin-dependent Diabetes Mellitus. J Pediatr Gastroenterol Nutr. 1996;23(1):29-33. PubMed PMID: 8811520.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - IgA antigliadin antibodies as a screening method for nonovert celiac disease in children with insulin-dependent diabetes mellitus. AU - Calero,P, AU - Ribes-Koninckx,C, AU - Albiach,V, AU - Carles,C, AU - Ferrer,J, PY - 1996/7/1/pubmed PY - 1996/7/1/medline PY - 1996/7/1/entrez SP - 29 EP - 33 JF - Journal of pediatric gastroenterology and nutrition JO - J. Pediatr. Gastroenterol. Nutr. VL - 23 IS - 1 N2 - One hundred forty-one children with insulin-dependent diabetes mellitus were screened for serum immunoglobulin A (IgA) antigliadin antibodies by means of an enzyme-linked immunosorbent assay (ELISA) method. None of them had gastrointestinal symptoms, and no major nutritional disturbances were detected except for a girl with moderate growth delay. Twelve patients with positive IgA antigliadin antibodies on two or more consecutive measurements underwent a small intestinal biopsy; four of them had a subtotal villous atrophy, and celiac disease was diagnosed; in another patient, a partial villous atrophy was observed. Children suffering from both diabetes and celiac disease showed an onset of diabetes at a younger age than did nonceliac patients. Prevalence of celiac disease in the screened population is 2.85%, which is higher than in the general population of the Comunidad Valenciana (one in 2,500 live births). SN - 0277-2116 UR - https://www.unboundmedicine.com/medline/citation/8811520/IgA_antigliadin_antibodies_as_a_screening_method_for_nonovert_celiac_disease_in_children_with_insulin_dependent_diabetes_mellitus_ L2 - http://dx.doi.org/10.1097/00005176-199607000-00006 DB - PRIME DP - Unbound Medicine ER -